

**Maria J. Antonelli, MD**

Assistant Professor of Medicine, Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH

**Irving Kushner, MD**

Emeritus Professor of Medicine, Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH

**Murray Epstein, MD, FASN, FACP**

Emeritus Professor of Medicine, Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL

# The constellation of vitamin D, the acute-phase response, and inflammation

**I**N 2016, LABORATORY TESTS to detect vitamin D deficiency were ordered more than 10 million times for Medicare patients, up 547% since 2007, at a cost of \$365 million.<sup>1</sup> In 2017, sales of vitamin D supplements totaled \$936 million, a 9-fold increase over the previous decade,<sup>1</sup> and expected to rise to \$1.3 billion by 2025, for an annual growth rate of 5.8% from 2020 to 2025.<sup>2</sup> This astronomic increase in vitamin D testing and supplementation is happening in the absence of any real evidence-based rationale.

See related editorial, page 91

## ■ UNCERTAINTY OF EVALUATING VITAMIN D STATUS

Evaluation of vitamin D status has long been problematic and plagued with confusion. At first, it was somewhat unclear as to which blood test—1,25-dihydroxyvitamin D or 25-hydroxyvitamin D (25[OH]D)—is the most informative. After 25(OH)D was settled on,<sup>3</sup> debate ensued over which blood levels are the most informative in assessing vitamin D status and what the cutoff points should be. It was concluded that the terms *insufficiency* and *deficiency* could be distinguished from one another, although they seem much the same to many clinicians. Even experts in the field of bone health cannot agree on which levels are acceptable (Table 1).<sup>3,4</sup>

## ■ IS VITAMIN D DEFICIENCY OR INSUFFICIENCY TRULY A PANDEMIC?

The prevalence of vitamin D deficiency is considered to be remarkably high: 41.6% of American adults had serum 25(OH)D levels below 20 ng/mL (50 nmol/L)

doi:10.3949/ccjm.90a.22048

in 2011,<sup>5</sup> levels considered to be consistent with vitamin D deficiency. The prevalence is high enough to be dubbed pandemic by some authors.<sup>6</sup> Worldwide, it has been estimated that 1 billion people have vitamin D deficiency or insufficiency,<sup>7</sup> which many find difficult to believe.<sup>7</sup> Much of this confusion is caused by the presumption that serum levels of 25(OH)D reflect nothing but vitamin D status. But is it possible that the levels are influenced by something else?

## ■ THE CASE FOR VITAMIN D AS A NEGATIVE ACUTE-PHASE REACTANT

The short answer is yes, there is compelling evidence that 25(OH)D is a negative acute-phase reactant—its serum levels decrease in the presence of inflammatory states.<sup>8–11</sup> Several lines of evidence support this conclusion:

- Serum C-reactive protein and 25(OH)D levels are inversely associated, as would be expected if 25(OH)D were a negative acute-phase reactant.<sup>12–16</sup> In quantitative terms, the inverse relation between 25(OH)D below its median and C-reactive protein levels was found to be significant: a geometric mean change in C-reactive protein of 0.11 mg/dL for each 10-ng/mL change in 25(OH)D (95% confidence interval 0.16 to -0.04) on multivariate linear regression analysis.<sup>12</sup>
- Low blood levels of 25(OH)D have repeatedly been found to be associated with a variety of inflammatory states.<sup>17–26</sup>
- Most tellingly, 25(OH)D levels fall after a variety of inflammatory insults, a classic test for acute-phase reactant behavior.<sup>9,10,27</sup> A surgical procedure, an induced inflammatory insult, may be associated with a 40% reduction in circulating 25(OH)D levels when compared with preoperative values.<sup>28</sup>

**TABLE 1**  
**Recommendations for deficiency and inadequacy of 25-hydroxyvitamin D**

<b>Endocrine Society<sup>3</sup></b>	
Deficiency	< 20 ng/mL (< 50 nmol/L)
Insufficiency	21–29 ng/mL (52.5–72.5 nmol/L)
Sufficiency	30–100 ng/mL (75–250 nmol/L)
<b>Institute of Medicine<sup>4</sup></b>	
At risk for deficiency	< 12 ng/mL (< 30 nmol/L)
At risk of inadequacy	12–19 ng/mL (30–49 nmol/L)
Sufficiency	20–50 ng/mL (50–125 nmol/L)
Concentration of possible concern	> 50 ng/mL (> 125 nmol/L)

- Low levels of 25(OH)D found in patients with obesity persist despite various aggressive vitamin D supplementation regimens, as would be expected of a negative acute-phase reactant.<sup>29</sup>

### ■ THE ACUTE-PHASE RESPONSE

The acute-phase response refers to a large number of behavioral, physiologic, biochemical, and nutritional changes that occur during inflammatory states. **Figure 1** shows examples of positive and negative acute-phase reactants.<sup>30</sup> A 1999 review reported that C-reactive protein and fibrinogen are prototypical positive acute-phase proteins whose plasma concentrations increase during inflammatory states, whereas albumin and transferrin are negative acute-phase proteins whose concentrations decrease.<sup>30</sup> Although the review largely focused on acute-phase proteins, the other components of the systemic response to inflammation should not be forgotten. Cations may also display acute-phase behavior. Examples include a decrease in concentrations of zinc and iron and an increase in copper concentration. Most significant for our purposes is research documenting the negative acute-phase behavior of a variety of vitamins.<sup>31</sup> This has been problematic for investigators and clinicians because the acute-phase behavior of these molecules tends to be overlooked. It has been noted that misclassification of vitamin A status can occur because serum retinol levels decrease during the acute-phase response.<sup>32</sup>

Similar problems are raised by other acute-phase reactants. Low serum albumin levels are often taken as evidence of malnutrition, although the low levels frequently reflect albumin's behavior as a negative acute-phase reactant. A similar tale can be told about

iron. While low serum iron levels may indicate iron deficiency, they may instead reflect an underlying inflammatory process. Clinicians are aided by the fact that transferrin, usually estimated by total iron binding capacity, is a negative acute-phase reactant. When low transferrin levels are found, it suggests the presence of an inflammatory process, whereas elevated transferrin values are usually seen in iron deficiency.

### ■ WHAT IS MEANT BY INFLAMMATION?

It is common for patients to ask us, "What can I do to lower my inflammation?" We should not be surprised by this. Patients are inundated with media reports that inform them that they can "fight inflammation" based on the premise that inflammation constitutes a single malicious process in the body. In fact, inflammation, a widely abused term, is not at all a simple process. It is a complex biological cascade that may involve, to varying degrees, a number of different cell types as well as multiple cytokines, histamines, bradykinin, prostaglandins, leukotrienes, platelet-activating factor, complement components, inflammasomes, and a family of molecules that promote cell adhesion. It is important that clinicians be aware of the complexity of these processes and impart that information to their patients.

Inflammation has classically been defined as a defense mechanism against infection and tissue injury, employing the innate immune response to localize and eliminate injurious factors and remove damaged tissue components. Its ultimate purpose is to return tissues to their normal state. A large number of medical conditions (eg, cardiovascular disease, obesity, type 2 diabetes), however, have been found to be associated with components of the inflammatory response, in the absence of infection or tissue injury. While it is generally presumed that inflammation participates in the pathogenesis of these conditions, it is equally likely that metabolic perturbations induce inflammation. Indeed, it has become apparent in the last decades that low-grade inflammation can be induced by tissue stress and malfunction ("metaflammation"), by changes from the optimal internal environment and the absence of infection or overt tissue injury.<sup>33,34</sup>

### ■ LOW-GRADE INFLAMMATION

Low-grade inflammation (metaflammation) differs from the inflammation resulting from infection or tissue injury. It is not accompanied by the 4 classic signs of inflammation—rubor (redness), tumor (swelling), calor (warmth), and dolor (pain)—and manifests


only minor degrees of C-reactive protein elevation, commonly regarded as an indicator of the presence of inflammation. While the purposes of classic inflammation are defense, healing, and tissue repair, the purpose of low-grade inflammation is the restoration of normal homeostasis. Acute inflammation is largely triggered by the pattern-recognition molecules PAMPs (pathogen-associated molecular patterns) and DAMPs (damage-associated molecular patterns), while low-grade inflammation is triggered by sentinel cells that monitor for deviations from the optimal homeostatic state.<sup>35,36</sup>

Low-grade inflammation is not rare. Modest C-reactive protein elevation, defined as concentrations between 3 and 10 mg/L, has been documented in approximately 30% of the US population.<sup>37</sup> Low-grade inflammation, manifested by modest C-reactive protein elevation, is associated with an astounding number of conditions and lifestyles, most of which are associated with poor health. These conditions represent or reflect minor metabolic perturbations, capable of inducing metaflammation. A partial list includes obesity, diabetes, atrial fibrillation, obstructive sleep apnea, hypertension, prehypertension, sleep deprivation, low levels of physical activity, lumbar disc herniation, polycystic ovary syndrome, various unhealthy diets, hypoxia, social isolation, and aging, as well as smoking and exposure to environmental irritants such as second-hand smoke.<sup>38</sup>

### ■ WHY SO MUCH INTEREST IN VITAMIN D?

It is well established that vitamin D is essential for skeletal health, but in recent years, evidence has been presented purporting to show that it plays a critical role in host defense<sup>39</sup> and in modulating both innate and adaptive immune responses.<sup>40</sup> It has been proposed that vitamin D administration inhibits inflammation and lowers the incidence of cancer and cardiovascular events.<sup>41</sup> Attempts have been made to link inadequate vitamin D levels to high susceptibility to chronic infections and to autoimmune diseases. Observational studies have found associations between low vitamin D levels and the risk of fractures, falls, mortality, diabetes, hypertension, and a variety of other disorders,<sup>42,43</sup> and a 2022 systematic review that found that patients with severe COVID-19 infection had lower levels of 25(OH)D than patients with milder infection.<sup>44</sup>

Based on the assumption that low 25(OH)D levels reflect nothing but less-than-optimal vitamin D status, clinical trials have been conducted, and more are in



**Figure 1.** Examples of positive and negative acute-phase reactants.

Based on information in reference 30.

progress, to determine whether vitamin D supplementation can reduce the likelihood that these conditions will occur or can avert severe disease associated with COVID-19. However, a nationwide, randomized, placebo-controlled trial found that supplementation with vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo,<sup>45</sup> a conclusion supported by other investigators who have similarly reported that vitamin D supplementation did not lead to significant reduction in all-cause mortality or mortality from cancer and cardiovascular disease.<sup>46,47</sup> And no significant difference has been found in major health-related outcomes in COVID-19 with vitamin-D supplementation.<sup>48,49</sup>

Are such clinical trials justified? One might argue that it is appropriate research, as there is much interest in the topic, and we do not have definitive answers. True. But the scientific rationale for carrying out such studies is undermined somewhat by the fact that vitamin D is a negative acute-phase reactant and that low levels of 25(OH)D may merely reflect metabolic perturbations.

### ■ THE SOCIETAL COST OF TOO MUCH CURIOSITY ABOUT VITAMIN D

As noted earlier, the increase in vitamin D testing and supplementation in the absence of a strong evidence base leads to an accelerating rise in economic costs. The Choosing Wisely Canada program<sup>50</sup> recommends checking serum 25(OH)D levels in patients with only a few select medical conditions (osteoporosis, inflammatory bowel disease, celiac disease, kidney and liver

disease, and pancreatitis) and recommends against testing in the general population. The Choosing Wisely campaign of the American Society for Clinical Pathology<sup>51</sup> also recommends against population-based vitamin D testing and recommends testing only in similar select populations. However, it states that laboratory testing is appropriate in higher-risk patients when results will be used to institute more aggressive therapy (eg, osteoporosis, chronic kidney disease, malabsorption, some infections, obesity).<sup>51</sup>

### ■ WHEN SHOULD WE RECOMMEND VITAMIN D SUPPLEMENTATION?

The high prevalence of low-grade inflammation in the general population argues against reflexively concluding that some degree of insufficiency or deficiency of vitamin D is present when a decreased concentration of serum 25(OH)D is found. Thus, finding a low vitamin D level in a patient whose C-reactive protein level is not elevated supports the possibility of vitamin D deficiency. However, finding an elevated C-reactive protein concentration or low albumin level is consistent with the possibility that systemic inflammation underlies the depressed 25(OH)D level, as well as the possibility that both vitamin D deficiency and systemic inflammation are present. In addition, the recent finding that the analytical per-

formance of immunoassays for 25(OH)D is highly variable further complicates the interpretation of laboratory test results.<sup>52</sup> All of this argues, of course, against routinely prescribing vitamin D supplements, even when low 25(OH)D levels are found.

### ■ THE NEXUS OF INFLAMMATION AND VITAMIN D: WHAT A MESS!

Much uncertainty lies in when to evaluate vitamin D, in the reliability of assays, in the significance of various 25(OH)D levels, and in the level of true deficiency. Often overlooked is the recognition that 25(OH)D levels may be low in the presence of both acute and low-grade inflammation and may represent a true nutritional deficiency. Despite expert guidance on when to determine vitamin D levels, many practicing clinicians are pressured into inappropriate ordering of this test and repleting “low” levels. We encourage conversations between clinicians and their patients regarding vitamin D testing and supplementation. ■

*Acknowledgment:* We are grateful to Nathan Berger, MD, for his helpful comments.

### ■ DISCLOSURES

Dr. Epstein has reported consulting for Bayer Healthcare. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

### ■ REFERENCES

1. Szabo L. Vitamin D, the sunshine supplement, has shadowy money behind it. The New York Times. August 18, 2018. <https://www.nytimes.com/2018/08/18/business/vitamin-d-michael-holick.html>. Accessed January 6, 2023.
2. Mordor Intelligence. United States vitamin D supplements market—growth, trends, Covid-19 impact, and forecasts (2022–2027). <https://www.mordorintelligence.com/industry-reports/united-states-vitamin-d-supplement-market-growth-trends-and-forecast>. Accessed January 6, 2023.
3. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab 2011; 96(12):3908]. J Clin Endocrinol Metab 2011; 96(7):1911–1930. doi:10.1210/jc.2011-0385
4. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96(1):53–58. doi:10.1210/jc.2010-2704
5. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 2011; 31(1):48–54. doi:10.1016/j.nutres.2010.12.001
6. Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017; 18(2):153–165. doi:10.1007/s11154-017-9424-1
7. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol 2014; 144 Pt A: 138–145. doi:10.1016/j.jsbmb.2013.11.003
8. Antonelli M, Kushner I. Low serum levels of 25-hydroxyvitamin D accompany severe COVID-19 because it is a negative acute phase reactant. Am J Med Sci 2021; 362(3):333–335. doi:10.1016/j.amjms.2021.06.005
9. Waldron JL, Ashby HL, Cornes MP, et al. Vitamin D: a negative acute phase reactant. J Clin Pathol 2013; 66(7):620–622. doi:10.1136/jclinpath-2012-201301
10. Silva MC, Furlanetto TW. Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review. Nutr Res 2015; 35(2):91–96. doi:10.1016/j.nutres.2014.12.008
11. Ghashut RA, Talwar D, Kinsella J, Duncan A, McMillan DC. The effect of the systemic inflammatory response on plasma vitamin 25(OH)D concentrations adjusted for albumin. PLoS One 2014; 9(3):e92614. doi:10.1371/journal.pone.0092614
12. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol 2012; 109(2):226–230. doi:10.1016/j.amjcard.2011.08.032
13. Bellia A, Garcovich C, D’Adamo M, et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2013; 8(1):33–40. doi:10.1007/s11739-011-0559-x
14. Yang F, Sun M, Sun C, et al. Associations of C-reactive protein with 25-hydroxyvitamin D in 24 specific diseases: a cross-sectional study from NHANES. Sci Rep 2020; 10(1):5883. doi:10.1038/s41598-020-62754-w
15. Xu S, Song J, Zhang ZH, et al. The vitamin D status is associated with serum C-reactive protein and adhesion molecules in patients with renal cell carcinoma. Sci Rep 2019; 9(1):16719. doi:10.1038/s41598-019-53395-9
16. Jin D, Zhu DM, Hu HL, et al. Vitamin D status affects the relation-



- ship between lipid profile and high-sensitivity C-reactive protein. *Nutr Metab (Lond)* 2020; 17:57. doi:10.1186/s12986-020-00455-x
17. **Holick MF.** The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. *Rev Endocr Metab Disord* 2017; 18(2):153–165. doi:10.1007/s11154-017-9424-1
  18. **Ginde AA, Mansbach JM, Camargo CA Jr.** Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2009; 169(4):384–390. doi:10.1001/archinternmed.2008.560
  19. **Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y.** Vitamin D in systemic and organ-specific autoimmune diseases. *Clin Rev Allergy Immunol* 2013; 45(2):256–266. doi:10.1007/s12016-012-8342-y
  20. **Chandrakar AK, Alexander A, R M, Rajendiran K, Ramasamy K.** 25-hydroxyl vitamin D deficiency in nasal polyposis. *Int Arch Otorhinolaryngol* 2020; 24(3):e308–e312. doi:10.1055/s-0039-3399541
  21. **Cheng S, Massaro JM, Fox CS, et al.** Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. *Diabetes* 2010; 59(1):242–248. doi:10.2337/db09-1011
  22. **Savastano S, Barrea L, Savanelli MC, et al.** Low vitamin D status and obesity: role of nutritionist. *Rev Endocr Metab Disord* 2017; 18(2):215–225. doi:10.1007/s11154-017-9410-7
  23. **Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB.** Obesity and vitamin D deficiency: a systematic review and meta-analysis. *Obes Rev* 2015; 16(4):341–349. doi:10.1111/obr.12239
  24. **Bang UC, Novovic S, Andersen AM, Fengler M, Hansen MB, Jensen JE.** Variations in serum 25-hydroxyvitamin D during acute pancreatitis: an exploratory longitudinal study. *Endocr Res* 2011; 36(4):135–141. doi:10.3109/07435800.2011.554937
  25. **Esnafoglu E, Subaşı B.** Association of low 25-OH-vitamin D levels and peripheral inflammatory markers in patients with autism spectrum disorder: vitamin D and inflammation in autism. *Psychiatry Res* 2022; 316:114735. doi:10.1016/j.psychres.2022.114735
  26. **Vieira NFL, do Nascimento CQ, da Silva Nascimento J, Vasconcelos SML, Barros-Neto JA, Dos Santos ACO.** 25-hydroxyvitamin D insufficiency and inflammation increase cardiovascular risk in older people. *Exp Gerontol* 2022; 165:111864. doi:10.1016/j.exger.2022.111864
  27. **Krishnan A, Ochola J, Mundy J, et al.** Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients. *Crit Care* 2010; 14(6):R216. doi:10.1186/cc9341
  28. **Reid D, Toole BJ, Knox S, et al.** The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. *Am J Clin Nutr* 2011; 93(5):1006–1011. doi:10.3945/ajcn.110.008490
  29. **Chakhtoura MT, Nakhoul NN, Shawwa K, Mantzoros C, El Hajj Fuleihan GA.** Hypovitaminosis D in bariatric surgery: a systematic review of observational studies. *Metabolism* 2016; 65(4):574–585. doi:10.1016/j.metabol.2015.12.004
  30. **Gabay C, Kushner I.** Acute-phase proteins and other systemic responses to inflammation [published correction appears in *N Engl J Med* 1999; 340(17):1376]. *N Engl J Med* 1999; 340(6):448–454. doi:10.1056/NEJM199902113400607
  31. **Louw JA, Werbeck A, Louw ME, Kotze TJ, Cooper R, Labadarios D.** Blood vitamin concentrations during the acute-phase response. *Crit Care Med* 1992; 20(7):934–941. doi:10.1097/00003246-199207000-00007
  32. **Stephensen CB, Gildengorin G.** Serum retinol, the acute phase response, and the apparent misclassification of vitamin A status in the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2000; 72(5):1170–1178. doi:10.1093/ajcn/72.5.1170
  33. **Antonelli M, Kushner I.** It's time to redefine inflammation [published correction appears in *FASEB J* 2017; 31(7):3206]. *FASEB J* 2017; 31(5):1787–1791. doi:10.1096/fj.201601326R
  34. **Hotamisligil GS.** Inflammation, metaflammation and immunometabolic disorders. *Nature* 2017; 542(7640):177–185. doi:10.1038/nature21363
  35. **Bianchi ME.** DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol* 2007; 81(1):1–5. doi:10.1189/jlb.0306164
  36. **Zindel J, Kubes P.** DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation. *Annu Rev Pathol* 2020; 15:493–518. doi:10.1146/annurev-pathmechdis-012419-032847
  37. **Woloshin S, Schwartz LM.** Distribution of C-reactive protein values in the United States. *N Engl J Med* 2005; 352(15):1611–1613. doi:10.1056/NEJM200504143521525
  38. **Kushner I, Rzewnicki D, Samols D.** What does minor elevation of C-reactive protein signify? *Am J Med* 2006; 119(2):166.e17–166.e1.66E28. doi:10.1016/j.amjmed.2005.06.057
  39. **Weiss ST, Litonjua AA.** Vitamin D in host defense: implications for future research. *Am J Respir Cell Mol Biol* 2017; 56(6):692–693. doi:10.1165/rcmb.2017-0064ED
  40. **Yin K, Agrawal DK.** Vitamin D and inflammatory diseases. *J Inflamm Res* 2014; 7:69–87. doi:10.2147/JIR.S63898
  41. **Zhang Y, Leung DY, Richers BN, et al.** Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. *J Immunol* 2012; 188(5):2127–2135. doi:10.4049/jimmunol.1102412
  42. **Annweiler C, Montero-Odasso M, Schott AM, Berrut G, Fantino B, Beauchet O.** Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects. *J Neuroeng Rehabil* 2010; 7:50. doi:10.1186/1743-0003-7-50
  43. **Heath AK, Kim IY, Hodge AM, English DR, Muller DC.** Vitamin D status and mortality: a systematic review of observational studies. *Int J Environ Res Public Health* 2019; 16(3):383. doi:10.3390/ijerph16030383
  44. **Pereira M, Dantas Damascena A, Galvão Azevedo LM, de Almeida Oliveira T, da Mota Santana J.** Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. *Crit Rev Food Sci Nutr* 2022; 62(5):1308–1316. doi:10.1080/10408398.2020.1841090
  45. **Manson JE, Cook NR, Lee IM, et al.** Vitamin D supplements and prevention of cancer and cardiovascular disease. *N Engl J Med* 2019; 380(1):33–44. doi:10.1056/NEJMoa1809944
  46. **Zhang Y, Fang F, Tang J, et al.** Association between vitamin D supplementation and mortality: systematic review and meta-analysis [published correction appears in *BMJ* 2020; 370:m2329]. *BMJ* 2019; 366:14673. doi:10.1136/bmj.l4673
  47. **Schoenmakers I.** Vitamin D supplementation and mortality. *Lancet Diabetes Endocrinol* 2022; 10(2):88–90. doi:10.1016/S2213-8587(22)00002-X
  48. **Rawat D, Roy A, Maitra S, Shankar V, Khanna P, Baidya DK.** Vitamin D supplementation and COVID-19 treatment: a systematic review and meta-analysis. *Diabetes Metab Syndr* 2021; 15(4):102189. doi:10.1016/j.dsx.2021.102189
  49. **Murai IH, Fernandes AL, Sales LP, et al.** Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. *JAMA* 2021; 325(11):1053–1060. doi:10.1001/jama.2020.26848
  50. **Choosing Wisely Canada.** Vitamin D tests. <https://choosingwisely-canada.org/vitamin-d-tests/>. Accessed January 6, 2023.
  51. **Choosing Wisely.** American Society for Clinical Pathology. Don't perform population based screening for 25-OH-vitamin D deficiency. Released February 21, 2013. <https://www.choosingwisely.org/clinician-lists/american-society-clinical-pathology-population-based-screening-for-vitamin-d-deficiency/>. Accessed January 6, 2023.
  52. **Altieri B, Cavalier E, Bhattoa HP, et al.** Vitamin D testing: advantages and limits of the current assays. *Eur J Clin Nutr* 2020; 74(2):231–247. doi:10.1038/s41430-019-0553-3

Address: Maria Antonelli, MD, Department of Medicine, Division of Rheumatology, MetroHealth Medical Center, 2500 MetroHealth Drive, H586, Cleveland, OH 44109; [mantonelli@metrohealth.org](mailto:mantonelli@metrohealth.org)